Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $129M | $177M | $202M | $207M | $208M | $216M | $316M | $487M | $614M | $883M |
| Revenue growth | — | 37.5% | 14.0% | 2.5% | 0.9% | 3.7% | 46.4% | 53.9% | 26.2% | 43.8% |
| Operating income | $20.1M | $28.3M | $35.4M | $16.4M | -$16.0M | -$39.8M | -$35.3M | $47.0M | $584K | $111M |
| Operating margin | 15.6% | 16.0% | 17.5% | 7.9% | -7.7% | -18.4% | -11.2% | 9.6% | 0.1% | 12.6% |
| Net income | $3.93M | -$1.08M | $15.5M | $6.09M | -$22.5M | -$42.6M | -$47.9M | $18.8M | -$18.5M | $78.3M |
| Net margin | 3.1% | -0.6% | 7.7% | 3.0% | -10.8% | -19.7% | -15.1% | 3.9% | -3.0% | 8.9% |
| EPS (diluted) | $0.34 | -$0.09 | $1.30 | $0.50 | -$1.88 | -$3.40 | -$3.05 | $0.85 | -$1.04 | $3.32 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $27.5M | $39.4M | $67.1M | $45.6M | $15.3M | $3.32M | -$31.2M | $119M | $64.0M | $185M |
| Capital expenditures | $4.57M | $10.4M | $5.74M | $6.63M | $6.13M | $2.56M | $8.88M | $8.87M | $16.2M | $13.8M |
| Free cash flow | $22.9M | $29.1M | $61.3M | $39.0M | $9.13M | $765K | -$40.1M | $110M | $47.8M | $171M |
| Share buybacks | $2.50M | $0.00 | $0.00 | $1.03M | $1.52M | $890K | $1.96M | $4.99M | $11.0M | $12.2M |
| Dividends paid | — | — | — | $0.00 | $0.00 | $190K | $1.63M | $1.63M | $1.63M | $1.16M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $27.4M | $31.1M | $43.0M | $62.3M | $7.86M | $100M | $48.2M | $221M | $145M | $286M |
| Total assets | $323M | $412M | $431M | $457M | $461M | $772M | $760M | $904M | $1.28B | $1.44B |
| Total liabilities | $153M | $237M | $233M | $244M | $265M | $413M | $422M | $447M | $856M | $900M |
| Long-term debt | $0.00 | $69.9M | $67.3M | $176M | $172M | $287M | $286M | $285M | $309M | $292M |
| Shareholders' equity | $170M | $175M | $197M | $213M | $196M | $334M | $314M | $433M | $404M | $541M |
| Retained earnings | -$2.92M | -$4.01M | $11.5M | $17.6M | -$4.97M | -$47.8M | -$97.3M | -$80.1M | -$100M | -$23.1M |
| Shares (wtd avg diluted) | 11.6M | 11.5M | 11.8M | 12.0M | 12.0M | 12.6M | 16.3M | 18.2M | 19.3M | 21.2M |
Every figure is extracted from ANI PHARMACEUTICALS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.